GlassScriptPhysician profile
Megan Robison
NPI 1134609324
$6,275.00
in general payments reported to CMS, 2019-2025
24 companies · $21.13 in 2025
The $21.13 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,134 · 2022: $2,031 · 2023: $1,036 · 2024: $51.94 · 2025: $21.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,109.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,280.62 | 2021-2023 | Lybalvi, Aristada, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $846.98 | 2021-2023 | |
| Neurocrine Biosciences, INC. | $822.34 | 2021-2023 | Ingrezza |
| Acadia Pharmaceuticals INC | $757.46 | 2021-2024 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $529.42 | 2021-2022 | |
| Abbvie INC. | $355.88 | 2021-2023 | |
| Sun Pharmaceutical Industries INC. | $235.21 | 2021 | |
| Janssen Pharmaceuticals, INC | $206.00 | 2021-2023 | Invega Sustenna |
| Indivior INC. | $186.50 | 2021-2023 | Perseris |
| Bausch Health US, LLC | $186.20 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $146.37 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $141.74 | 2021 | |
| Jazz Pharmaceuticals INC. | $121.61 | 2021-2022 | |
| Bioxcel Therapeutics, INC. | $120.11 | 2023 | Igalmi |
| Takeda Pharmaceuticals U.S.A., INC. | $94.16 | 2021-2023 | Trintellix |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $83.82 | 2021-2022 | |
| Tris Pharma INC | $25.42 | 2022 | |
| Eisai INC. | $24.73 | 2021 | |
| Axsome Therapeutics, INC. | $21.20 | 2023 | Auvelity |
| Alexion Pharmaceuticals, INC. | $21.13 | 2025 | Strensiq |
| Ironshore Pharmaceuticals INC. | $19.88 | 2021 | |
| Merck Sharp & Dohme LLC | $18.18 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.66 | 2023 | Quviviq |
| Biogen, INC. | $13.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Robison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.